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lymphocytic leukemia (CLL) with ibrutinib results in high
rates of progression-free and overall survival. Ibrutinib, an
irreversible Bruton’s tyrosine kinase inhibitor, may also
modulate donor T cell alloimmunity via interleukin-2-
inducible kinase inhibition. We report results of ibrutinib
salvage therapy in 5 high risk CLL patients who relapsed
following allogeneic hematopoietic cell transplantation
(allo-HCT). Lymph node (LN) size was measured by CT
scan, CLL minimal residual disease (MRD) levels by IgH
high-throughput sequencing (HTS) (ClonoSIGHTTM test,
Sequenta Inc.), donor CD3 chimerism by short tandem
repeat analysis, and donor B cell immune reconstitution
by IgH HTS quantiﬁcation of total IgH molecules and
unique IgH clonotypes.
Results: All 4 patients with pathologic lymphadenopathy
prior to treatment experienced dramatic LN reduction on
ibrutinib (Fig 1A; 68% average reduction after 3 mos). Pa-
tients SPN3975 (17p del) and SPN3431 (11q del) achieved
undetectable CLL MRD (<10-6) after 39 mos and 8 mos,
respectively (Fig 1B, 1C). SPN3975 had failed to maintain full
donor CD3 chimerism after dose-escalated donor lympho-
cyte infusions but after 1 yr of ibrutinib achieved full donor
chimerism. Oral and skin chronic graft-versus-host disease
(cGVHD) additionally resolved after 6 mos. Two additional
patients have increased donor chimerism since starting
ibrutinib. Although SPN3975 has not taken ibrutinib for >10
mos, full donor chimerism persists and CLL MRD remains
undetectable (Fig 1B). Prior to ibrutinib, donor B cells in this
patient (excluding the CLL clone) accounted for<0.2% of total
PBMC. Following discontinuation of ibrutinib, donor B cells
increased within 6 mos and now comprise >1% of PBMC (Fig
1D). Furthermore, recovering B cells have diverse, low fre-
quency IgH clonotypes (Fig 1E).
Conclusions: Ibrutinib provides effective salvage therapy for
CLL relapse following allo-HCT and demonstrates promising
donor immune modulation, promoting full donor chimerism
and cGVHD resolution. Here we present 2 post allo-HCT CLL
relapse patients who achieved MRD negativity on ibrutinib,
one of whom maintains undetectable CLL 10 mos after
stopping therapy. Our ﬁndings show rapid, sustained, and
diverse immune reconstitution without CLL recurrence
following discontinuation. Clinical trials are needed to
determine the duration of therapy for post allo-HCT relapse,
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Introduction: DCBT in children with acute leukemia is
controversial given the ﬁndings of the recent BMT CTN ran-
domized study. However, many children will not have
adequate single-units based on the recent CIBMTR analysis
(cryopreserved TNC > 3.0 x 107/kg and 6-8/8 allele donor-
recipient HLA-match).
Methods: We analyzed 35 consecutive pediatric DCBT pa-
tients (pts) treated for acute leukemia (10/2005-2/2013). All
CBT recipients in this period received 2 units.
Results: Median pt age was 7.5 yrs (range 0.8-18), median
weight was 28 kg (range 8-75), and 69% had non-European
ancestry. Seventeen pts had AML: 6 CR1 (one each with M7,
secondary 5q- MDS, FLT-3 ITD, Ph+, Down syndrome MRD+,
germline mutation CEBPa), 8 CR2 (one MLL MRD+), 1 CR3,
and 2 in aplasia. Seventeen pts had ALL: 10 CR1 [3 Ph+ (one
MRD+), 2 T-cell ALL, 1 MLL, 1 L3 disease, and 3 multiple
inductions], 4 CR2, 3 CR3. One pt had advanced CML. Con-
ditioning was Cy120/Flu/TBI1375 (N ¼ 21, 60%) or chemo-
therapy-only (N ¼ 14, 40%, 10 Clo/Mel/Thio, 4 Bu/Mel/Thio).
GVHD prophylaxis was CNI/MMF. Units had a high degree of
donor-recipient HLA-allele disparity (Table). The cumulative
incidence of sustained donor neutrophil engraftment was
94% (95%CI:78-98, median 21 days, range 12-33), and he-
matopoiesis was mediated by a single unit. Day +180 platelet
engraftment  50 x 109/l was 82% (95%CI: 64-92, median 51
days, range 39-299). CD4+ count recovery was prompt: mean
day 60 201 (SD:+/-180), and day 120 250 (SD:+/-150). Of 33
engrafted pts, 10 (30%) engrafted with a unit with pre-
cryopreservation TNC < 2.5 x 107/kg, and 17 (51%) engrafted
with a unit  5/8 HLA-allele matched. The cumulative inci-
dence of day 100 grade II-IV acute GVHDwas 46% (95%CI:29-
61), and 23% (95%CI:11-38) had grade III-IV acute GVHD.
3-year chronic GVHD was 14% (95%CI:5-28). With a median
58 month (range 20-105) follow-up, the 3-year cumulative
incidence of TRM was 11% (95%CI:4-24); deaths were due to
graft failure (2), HHV-6 encephalitis (1), and viral pneumonia
(1). Relapse at 3 years was 20% (95%CI:9-35): 2 AML CR1 (one
FLT-3 ITD, one M7), one previously refractory AML, and 4 ALL
(2 CR1, 1 CR2, 1 CR3). None of the 4 pts transplanted with
MRD+ relapsed. Three-year DFS was 68% (95%CI:50-81), with
no difference based on diagnosis (p¼ 0.25, Figure), TBI-based
cytoreduction (p ¼ 0.68), or non-European ancestry (p ¼
0.24).
Table
Donor-recipient 8 HLA-allele match (N ¼ 70 units)
1 2 3 4 5 6 7 8 (N)
6/6 25% 25% 25% 25% 4
5/6 5% 19% 26% 35% 16% 43

















1 23/M MRD CR3 4.65 1 x 106 23; 75 Grade 1
GVHD
2 24/M MUD CR3 5.14 1 x 105 24; 87 Grade 1
GVHD
3 25/F MRD CR3 8.69 1 x 106 23 None
4 18/M MRD CR2 4.88 1 x 106 22; 54 None
5 18/M MUD CR4 9.45 1 x 105 24 Too early
6 6/M MUD CR3 10 1 x 105 26 Too early
Disease status: CR¼complete remission #
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very high degree of donor-recipient HLA-allele mismatch,
the low TRM and relapse rates after pediatric DCBT are
striking, with either TBI-based or chemotherapy-only con-
ditioning. Although young children could have adequate
single-unit grafts, a signiﬁcant percentage will not. There-
fore, DCBT remains an important consideration, especially
for children of ethnic minorities.
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Background: Relapse is the primary cause of treatment
failure following allogeneic HCT. Preclinical data demon-
strates that large numbers of activated NK cells can be
generated ex vivo using artiﬁcial APCs (aAPC), that these
activated NK cells readily kill pediatric leukemia, and that
activity is independent of KIR mismatch. The post-transplant
period may be favorable for expansion and survival of
adoptively transferred NK cells potentially providing an
additional anti-leukemia effect.
Methods: We initiated a Phase I trial to assess safety and
feasibility of administration of escalating doses of donor-
derived activated NK cell infusions (NK-DLI) following mye-
loablative HLA-matched T-cell depleted PBSCT. Donors
underwent apheresis for ﬁlgrastim mobilized PBSC. The
product was T cell depleted and CD34/CD56 selected. The
CD56+ fractionwas cultured for 9e11 days with a K562 based
aAPC expressing 4-1BBL and IL-15Ra plus rhIL-15 to generate
the NK-DLI. T cell add back to the CD34 selected graft ranged
from 1-2 x 10e4 T cells/kg. NK-DLI was administered at days
21 and 49 (+/- 3 days) post-transplant. Patients received a
myeloablative preparative regimen (TBI 1200 cGy and
cyclophosphamide 60 mg/kg x 2 days). Recipients of unre-
lated donor products received GVHD prophylaxis with
tacrolimus and were dose escalated separately. The starting
dose for NK-DLI was 1 x 105 NK cells/kg for unrelated donor
recipients and 1 x 106 NK cells/kg for related donor
recipients.
Results: Six patients with high-risk ALL underwent trans-
plant (Table). The median time to neutrophil and platelet
engraftment was 9 and 12 days respectively. Median whole
blood and CD3 donor chimerism at day 28 was 91% (range,
49-100%) and 52% (range, 0-97%). Despite achieving primary
engraftment, one patient had absence of donor lymphoid
engraftment and underwent a second RIC T-replete HCT to
treat secondary rejection. Another subject received DLI to
treat mixed chimerism. Although persistence or engraftmentof infused NK-DLI cannot be deﬁnitely determined, in 5 of 6
recipients, the absolute NK value post-infusionwas a median
of 2.8 fold higher (range 1.7-4.3) than the pre-infusion value.
Two subjects had grade 1 GVHD. All subjects received the
second NK infusion off any immunosuppression. With
limited follow up, all patients remain disease free (2-12
months post-HCT).
Conclusions: Infusion of ex-vivo, aAPC expanded NK-DLI is
feasible and can be safely performed followingmyeloablative
allogeneic HCT in patients with high-risk leukemia. Accrual
and follow-up are ongoing.447
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Introduction: Unrelated donor (UD) attrition is a serious
problem impacting patients awaiting a transplant. In 2011
we presented results from a study of 7541 UD showing that
donor attrition at CT was 38.2% and signiﬁcantly worse in
women, ethnic minorities, non-blood donors and those be-
ing on the register longer.
Since then 3 signiﬁcant changes have been made: the
joining age was reduced to 16-30 (previously 18-40), the
maximum BMI allowed for PBSC donors was increased from
35 to 40 and an improved tracing system for uncontactable
donors was introduced.
The objective of this work was to assess the impact of
these changes on the proportion of donors involved in the
cancellation of requests.
Methods: All CT requests made from Anthony Nolan in 2013
were reviewed, and outcomes documented. For each request,
donor characteristics were documented.
Results: In 2013, 4207 requests were performed; 56.8% were
completed, while 37.7% were cancelled for donor reasons.
The univariate analysis showed that longer duration on the
register (p<0.001), not being a blood donor (p<0.001) and
African, African-Caribbean and Asian ethnicities (p<0.001)
were associated with higher attrition rates.
Compared to our previous study we found similar attri-
tion rates overall (38.2% to 37.7%; p¼0.6). However, therewas
a reduction in donor cancellations for medical reasons (30%
to 14.8%; p < 0.001). Conversely, we found that the attrition
rates due to emigration or travel had increased (7.9% to 13%;
p<0.001).
